Bullfrog AI Holdings, Inc.
NASDAQ:BFRG
Bullfrog AI Holdings, Inc.
BullFrog AI Holdings, Inc. is a digital biopharmaceutical company, which engages in artificial intelligence and machine learning driven analysis of complex data sets in medicine and healthcare. The company is headquartered in Gaithersburg, Maryland and currently employs 2 full-time employees. The company went IPO on 2023-02-14. The firm is focused on advanced artificial intelligence/machine learning (AI/ML)-driven analysis of complex data sets in medicine and healthcare. Its platform technology, bfLEAP, is an analytical AI/ML platform, which is a potentially disruptive tool for analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize it against other disparate data sources from patients. The Company’s therapeutic pipeline includes siRNA and Mebendazole. Its siRNA targeting Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma (HCC), treatment of obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.
BullFrog AI Holdings, Inc. is a digital biopharmaceutical company, which engages in artificial intelligence and machine learning driven analysis of complex data sets in medicine and healthcare. The company is headquartered in Gaithersburg, Maryland and currently employs 2 full-time employees. The company went IPO on 2023-02-14. The firm is focused on advanced artificial intelligence/machine learning (AI/ML)-driven analysis of complex data sets in medicine and healthcare. Its platform technology, bfLEAP, is an analytical AI/ML platform, which is a potentially disruptive tool for analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize it against other disparate data sources from patients. The Company’s therapeutic pipeline includes siRNA and Mebendazole. Its siRNA targeting Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma (HCC), treatment of obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.
